Selective Inhibition of the ABCG2 Transporter by Primaquine Derivatives Reverses the Multidrug Resistance of Tumor...

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Cancer Biology

Background:

• Multidrug resistance (MDR) is a major obstacle in cancer treatment, often caused by ATP-binding cassette (ABC) transporters like ABCG2.
• ABCG2 actively removes chemotherapy drugs from cancer cells, reducing treatment efficacy.

Purpose of the Study:

• To investigate the effects of novel primaquine derivatives, fumardiamides and bis-ureas, on P-glycoprotein (P-gp) and ABCG2 transporter activity.
• To evaluate the potential of these derivatives in reversing MDR.

Main Methods:

• Synthesis and characterization of fumardiamide and bis-urea derivatives of primaquine.
• Functional assays to assess inhibition of P-gp and ABCG2.
• Cytotoxicity assays and assessment of ABCG2 expression and localization.
• Evaluation of MDR reversal in drug-resistant cancer cell lines.

Main Results:

• Fumardiamide derivatives (1a, 1b, 1d) potently and selectively inhibited ABCG2 without affecting P-gp.
• These compounds exhibited low to moderate cytotoxicity and did not alter ABCG2 expression or localization.
• The derivatives enhanced the sensitivity of resistant cancer cells to mitoxantrone, indicating MDR reversal.

Conclusions:

• Primaquine-based fumardiamides are selective ABCG2 inhibitors.
• These compounds demonstrate potential for overcoming ABCG2-mediated MDR in cancer therapy.
• Further development of these derivatives could lead to novel therapeutic strategies for MDR cancers.